Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan in Children With Refractory Solid Tumors
NCT00004078Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Oct 1999
- Primary completion
- Oct 2007
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in solid tumor, central nervous system tumor, neuroblastoma, Ewing sarcoma, Peripheral Primitive Neuroectodermal Tumor (pPNET), sponsored by Children's Oncology Group. Started Oct 1999; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
solid tumorcentral nervous system tumorneuroblastomaEwing sarcomaPeripheral Primitive Neuroectodermal Tumor (pPNET)
Beyond the preview
Go deeper on NCT00004078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004078.